WillItSurvive
Medical technology and health companies · United States

Woebot Health

woebothealth.com ↗

Maker of a scripted mental health chatbot, now shut down its consumer app and pivoting to enterprise deals.

Little protection left
Assessed 22 July 2026 · Evidence as of 22 July 2026
Not much stands between this business and its pressures.
On the recordSince 22 July 2026 · Checkable from next 6 months · Every call on the record Checkpoint: Any new funding round announcement or FDA marketing authorization for WB001
The call

Woebot shut its consumer app after generative AI ate its use case, and now runs on two enterprise contracts and an unconverted FDA designation with no new funding since 2022.

Woebot Health built a scripted chatbot to help people with mental health issues, but it was replaced by ChatGPT and Claude, which do the same thing better and faster without waiting for government approval. The company closed its consumer app in June 2025 because FDA rules made it too slow and expensive to compete, and it is now trying to sell to employers with just two customers and no new investment since 2020. The company could change course if it gets FDA approval and insurance companies actually pay for its old product WB001, which would give it something the free AI tools cannot easily do, but that has not happened in five years.

Why
01
AI pressure: OpenAI ChatGPT, Anthropic Claude, Google Gemini. Founder says generative AI moved faster than regulators, replacing Woebot's scripted bot and killing the consumer app in June 2025. Could AI do the core job? Yes, likely.
02
Bigger players: Lyra Health, Spring Health, Modern Health, Wysa, Headspace, Talkspace. These enterprise behavioral health vendors already sit inside the employer and payer contracts Woebot now needs. Could a giant copy it? Yes, easily.
03
What protects it. An FDA Breakthrough Designation for WB001 that has not converted to a marketing authorization in five years.
What would change this call
Woebot announces a new funding round within 6 months. Would show investors still see a viable path beyond wind-down.
FDA grants marketing authorization (not just Breakthrough Designation) for WB001. Would show the regulatory seal finally converts to a shippable product.
Woebot names new enterprise or payer contracts with growth metrics beyond Akron Children's and Virtua Health. Would show the enterprise pivot is gaining real traction, not just two logos.
Key numbers
  • 1.5M lifetime consumer app users (2025-07-02)
  • $123M total raised across 9 rounds (2022-03-14)
  • Only 2 named enterprise partners: Akron Children's, Virtua Health (2024-08-01)
Named risks
  • No new funding disclosed since March 2022, raising insolvency or wind-down risk. Severity: high
  • Consumer flagship product already discontinued June 30, 2025 with unproven enterprise pivot. Severity: high
  • FDA Breakthrough Designation for WB001 never converted to marketing authorization in 5 years. Severity: medium
  • Crowded enterprise behavioral health market with entrenched, better-capitalized rivals. Severity: medium
  • Core technology (scripted, non-generative bot) structurally outcompeted by generic LLMs. Severity: high
Rivals, as read in July 2026
RivalDirectionEvidence
OpenAI ChatGPT, Anthropic Claude, Google Geminilosing toFounder cites LLMs as proximate cause of consumer app shutdown, June 30, 2025
Wysalosing toHybrid AI plus clinician model cited as gaining share over pure chatbots, August 2025
Lyra Health, Spring Health, Modern Healthlosing toAlready entrenched, better-funded incumbents in enterprise behavioral health market, 2026
Talkspace, Headspace/GingercontestingEstablished teletherapy and workplace mental health benefit providers in same market
Questions people ask
Is Woebot Health still operating in 2026?
Yes, but only as a B2B enterprise vendor. Woebot shut down its consumer app on June 30, 2025, and pivoted to distributing its tool through payer, provider, and employer access codes; as of May 2026 the consumer app remains unavailable for download.
Why did Woebot Health shut down its consumer chatbot app?
Founder Alison Darcy told STAT News (July 2, 2025) the shutdown stemmed from the high cost of FDA marketing authorization combined with generative LLMs like GPT-4 moving faster than regulators, making Woebot's scripted, non-generative bot obsolete.
Could ChatGPT or other AI chatbots replace Woebot Health's product?
They already have. Woebot's core product was a scripted, rules-based CBT chatbot, and third-party sources report GPT-4 class LLMs outperformed it on therapeutic conversation tasks, contributing directly to the June 30, 2025 consumer shutdown.
Is Woebot Health profitable or well funded?
No recent funding or revenue has been disclosed. Woebot raised roughly $123 million total, with its last round a $9.5 million Bayer investment in March 2022; no new capital or public revenue figures have surfaced since, as of mid-2026.
Who owns Woebot Health and has it been acquired?
Woebot Health (legally Woebot Labs, Inc.) remains an independently owned, privately held company as of mid-2026, backed by investors including NEA, JAZZ Venture Partners, Temasek, Owl Ventures, and Leaps by Bayer; no acquisition has been reported.
Who are Woebot Health's biggest competitors?
PitchBook lists about 25 competitors including Spring Health, Brightline, Wysa, Modern Health, and Lyra Health as of 2026. Wysa in particular is cited as gaining ground with a hybrid AI-plus-licensed-clinician model since Woebot's pure chatbot approach struggled.
Timeline
  • 2026-05Third-party tracker confirms Woebot consumer app still unavailable for download
  • 2025-08Telehealth commentary says Wysa's hybrid model gains where pure chatbots struggled
  • 2025-07-02STAT News: founder attributes shutdown to FDA costs and LLM competition
  • 2025-06-30Woebot consumer app officially shut down
  • 2025-04-25Woebot announces consumer app retirement effective June 30, 2025
  • 2024-08Woebot partners with Akron Children's Hospital, 44 pediatric facilities
  • 2022-03Woebot raises $9.5M venture round from Leaps by Bayer
  • 2021-07-21Woebot closes $90M Series B led by JAZZ Venture Partners and Temasek
  • 2021-01WB001 postpartum depression product receives FDA Breakthrough Device Designation
  • 2018-03Woebot raises $22.8M Series A led by AI Fund and NEA
Revision history
22 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Winning Health TechnologyCarbon Health111 Inc
More in Medical technology and health companies →
Sources